2型糖尿病与胰腺癌：一段正在展开的历史。
Diabetes Type 2 and Pancreatic Cancer: A History Unfolding.
作者信息
De Souza Andre, Irfan Khawaja, Masud Faisal, Saif Muhammad Wasif
机构信息
Department of Hematology and Oncology, Tufts Medical Center, Boston, MA, USA.
Department of Endocrinology and Metabolism, Services Institute of Medical Sciences, Lahore, Pakistan.
出版信息
JOP. 2016 Mar;17(2):144-148.
Abstract
Pancreatic Cancer is the fourth cause of cancer-related deaths in the United States. Up to 80% of pancreatic cancer patients present with either new-onset type 2 diabetes or impaired glucose tolerance at the time of diagnosis. Recent literature suggests that diabetes mellitus type 2 is a risk factor, a manifestation and a prognostic factor for pancreatic cancer. This article is intended to clarify the evidence about diabetes as a risk factor for pancreatic cancer.
摘要
胰腺癌是美国癌症相关死亡的第四大原因。高达80%的胰腺癌患者在确诊时伴有新发2型糖尿病或糖耐量受损。最近的文献表明，2型糖尿病是胰腺癌的一个危险因素、一种表现形式和一个预后因素。本文旨在阐明关于糖尿病作为胰腺癌危险因素的证据。
相似文献
1
Diabetes Type 2 and Pancreatic Cancer: A History Unfolding.
JOP. 2016 Mar;17(2):144-148.
2
Risk factor, early diagnosis and overall survival on outcome of association between pancreatic cancer and diabetes mellitus: Changes and advances, a review.
Int J Surg. 2018 Apr;52:342-346. doi: 10.1016/j.ijsu.2018.02.058. Epub 2018 Mar 10.
3
Pancreatic cancer and glucose metabolism.
Turk J Gastroenterol. 2009 Dec;20(4):257-60. doi: 10.4318/tjg.2009.0022.
4
Type 2 Diabetes Mellitus and Its Association with the Risk of Pancreatic Carcinogenesis: A Review.
Korean J Gastroenterol. 2016 Apr 25;67(4):168-77. doi: 10.4166/kjg.2016.67.4.168.
5
Diabetes and pancreatic cancer.
JOP. 2014 Mar 10;15(2):118-20. doi: 10.6092/1590-8577/2286.
6
[Pancreatic carcinoma and diabetes mellitus].
Cas Lek Cesk. 2004;143(2):97-100.
7
Diabetes mellitus and pancreatic cancer mortality in a prospective cohort of United States adults.
Cancer Causes Control. 1998 Aug;9(4):403-10. doi: 10.1023/a:1008819701485.
8
Diabetes: risk factor for the development of pancreatic cancer or manifestation of the disease?
World J Surg. 2001 Apr;25(4):503-8. doi: 10.1007/s002680020344.
9
Metformin and pancreatic cancer: Is there a role?
Cancer Chemother Pharmacol. 2016 Feb;77(2):235-42. doi: 10.1007/s00280-015-2948-8. Epub 2016 Jan 6.
10
Pancreatic cancer and sugar diabetes.
Nutr Rev. 2001 Apr;59(4):112-5. doi: 10.1111/j.1753-4887.2001.tb06997.x.
引用本文的文献
1
Clot formation, structure, and fibrinolysis of plasma from pancreatic cancer patients.
J Thromb Thrombolysis. 2025 Jul 14. doi: 10.1007/s11239-025-03118-x.
2
New onset diabetes predicts clinical outcomes in patients with pancreatic adenocarcinoma.
J Gastrointest Oncol. 2025 Feb 28;16(1):226-233. doi: 10.21037/jgo-24-570. Epub 2025 Feb 26.
3
Clot formation, structure, and fibrinolysis of pancreatic cancer patients.
Res Sq. 2025 Feb 11:rs.3.rs-5868575. doi: 10.21203/rs.3.rs-5868575/v1.
4
Repurposing metabolic regulators: antidiabetic drugs as anticancer agents.
Mol Biomed. 2024 Sep 28;5(1):40. doi: 10.1186/s43556-024-00204-z.
5
PANC-1 Cell Line as an Experimental Model for Characterizing PIVKA-II Production, Distribution, and Molecular Mechanisms Leading to Protein Release in PDAC.
Int J Mol Sci. 2024 Mar 20;25(6):3498. doi: 10.3390/ijms25063498.
6
Retrospective evaluation of toceranib phosphate (Palladia) use in the treatment of feline pancreatic carcinoma.
Can Vet J. 2023 Dec;64(12):1143-1148.
7
A niche-mimicking polymer hydrogel-based approach to identify molecular targets for tackling human pancreatic cancer stem cells.
Inflamm Regen. 2023 Sep 27;43(1):46. doi: 10.1186/s41232-023-00296-0.
8
New-Onset Diabetes after an Obesity-Related Cancer Diagnosis and Survival Outcomes in the Women's Health Initiative.
Cancer Epidemiol Biomarkers Prev. 2023 Oct 2;32(10):1356-1364. doi: 10.1158/1055-9965.EPI-23-0278.
9
Enlightening the molecular mechanisms of type 2 diabetes with a novel pathway clustering and pathway subnetwork approach.
Turk J Biol. 2022 Jul 18;46(4):318-341. doi: 10.55730/1300-0152.2620. eCollection 2022.
10
Role of Pancreatic Tumour-Derived Exosomes and Their Cargo in Pancreatic Cancer-Related Diabetes.
Int J Mol Sci. 2023 Jun 15;24(12):10203. doi: 10.3390/ijms241210203.
本文引用的文献
1
Genomics-enabled drug repositioning and repurposing: insights from an IOM Roundtable activity.
JAMA. 2014 May;311(20):2063-4. doi: 10.1001/jama.2014.3002.
2
Diabetes and pancreatic cancer.
JOP. 2014 Mar 10;15(2):118-20. doi: 10.6092/1590-8577/2286.
3
Vaccine therapy for pancreatic cancer.
Oncoimmunology. 2013 Dec 1;2(12):e26662. doi: 10.4161/onci.26662. Epub 2013 Oct 22.
4
Epigenetic targeting in pancreatic cancer.
Cancer Treat Rev. 2014 Jun;40(5):656-64. doi: 10.1016/j.ctrv.2013.12.002. Epub 2014 Jan 3.
5
Epigenome-wide association study of fasting measures of glucose, insulin, and HOMA-IR in the Genetics of Lipid Lowering Drugs and Diet Network study.
Diabetes. 2014 Feb;63(2):801-7. doi: 10.2337/db13-1100. Epub 2013 Oct 29.
6
The stromal compartments in pancreatic cancer: are there any therapeutic targets?
Cancer Lett. 2014 Feb 28;343(2):147-55. doi: 10.1016/j.canlet.2013.09.039. Epub 2013 Oct 16.
7
Diabetes and pancreatic cancer.
JOP. 2013 Jul 10;14(4):363-6. doi: 10.6092/1590-8577/1656.
8
Influence of gut microbiota on subclinical inflammation and insulin resistance.
Mediators Inflamm. 2013;2013:986734. doi: 10.1155/2013/986734. Epub 2013 Jun 12.
9
Metformin-mediated growth inhibition involves suppression of the IGF-I receptor signalling pathway in human pancreatic cancer cells.
BMC Cancer. 2013 May 10;13:235. doi: 10.1186/1471-2407-13-235.
10
The role of adipokines in β-cell failure of type 2 diabetes.
J Endocrinol. 2013 Jan 2;216(1):T37-45. doi: 10.1530/JOE-12-0278. Print 2013 Jan.
Zotero 插件